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Abstract
 Incidence and mortality from cervical cancer have remainedBackground:
high due to many obstacles facing the implementation of organized
screening programs in resource-constrained countries such as Nigeria. The
application of mobile technologies (mHealth) to health services delivery has
the potential to reduce inequalities, empower patients to control their health,
and improve the cost-effectiveness of health care delivery.
 To assess the efficacy of mobile technology intervention on Pap testAim:
screening adherence compared to a control condition and also determine
the factors affecting the uptake of Pap smear screening practices among
women in Lagos.
 This is a multi-center randomized controlled trial that will involveMethods:
women aged 25 to 65 years attending the General Outpatient clinics of the
two tertiary health institutions in Lagos, Nigeria between April and
December 2020. At baseline, a total of 200 National Health Insurance
Scheme (NHIS) enrollees will be randomized to either a text message arm
or usual care (control) arm. The primary outcome is the completion of a Pap
smear within 6 months of enrolment in the study. The associations between
any two groups of continuous variables will be tested using the independent
sample t-test (normal distribution) or the Mann-Whitney U test (skewed
data) and that of two groups of categorical variables with Chi-square  orX
Fisher's exact test where appropriate. Using binary logistic regression
model, we will adjust for age and other relevant sociodemographic and
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 model, we will adjust for age and other relevant sociodemographic and
clinical variables and adherence to Pap test screening. Statistical
significance will be defined as  -value less than 0.05.P
The mHealth-Cervix study will evaluate the impact of mobileDiscussion: 
technologies on cervical cancer screening practices in Lagos, Nigeria as a
way of contributing to the reduction in the wide disparities in cervical cancer
incidence through early detection facilitated using health promotion to
improve Pap smear screening adherence.
:   13/02/2020Registration PACTR202002753354517
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Introduction
Cervical cancer is a major public health problem and is the 
fourth most common cancer in women worldwide account-
ing for an estimated 570,000 new cases annually1. More than 
80% of the global burden of cervical cancer occurs in the less 
developed regions, where it accounts for almost 12% of all 
female malignancies2,3. In 2018, an estimated 311,000 deaths 
were attributed to cervical cancer, which accounts for 7.5% of 
all female cancer deaths with 70% of these occurring in devel-
oping countries1. Early detection of precursor lesions of cer-
vical cancer through the use of screening tests has drastically 
reduced the incidence of the disease, especially in Western 
countries where Pap smear (cytology-based) screening has 
been introduced and now covers almost all eligible women4. 
However, in resource-constrained countries of the world such as 
Nigeria, cervical cancer incidence and mortality have remained 
high due to the many obstacles facing the implementation of 
organized screening programs5. A recent study conducted by 
our team among women in Lagos revealed Pap smear screening 
uptake of about 23% despite an awareness rate of 55%6.
The use of mobile technologies has increased exponentially 
in the last few years7. We reported in a study conducted in 
2018 that mobile telephones could be found in 95% of house-
holds in Lagos and these were widely distributed across 
all socioeconomic classes8. Because of this increased access to 
technologies, mobile health (mHealth), or “medical and pub-
lic health practice involving the use of mobile devices”9, has 
great potential in many health areas such as promotion and 
prevention10. The World Health Organization (WHO) report 
on mHealth in 20119 states that mobile health strategies exist 
in at least 75% of the countries in WHO regions. The appli-
cation of mHealth to health services delivery has the poten-
tial to reduce inequalities, empower patients to control their 
health, and improve the cost-effectiveness of health care 
delivery11.
Although still limited, there is growing evidence of success in 
the use of mobile phones for health (mHealth technologies) to 
support cancer prevention12–15. Nevertheless, there is currently no 
reported randomized controlled trial in sub-Saharan Africa (sSA) 
that examines the use of mobile health technologies in cancer 
prevention. This study will, therefore, aim to ascertain the effi-
cacy of an intervention using mobile technologies on Pap 
smear screening adherence compared to standard care; and also 
determine the factors affecting the uptake of Pap smear screen-
ing services among women in Lagos, Nigeria. The introduc-
tion of mHealth, now regarded as one of the most promising 
investments for health in developing countries16, is a key inno-
vative concept that will offer a unique opportunity for a para-
digm shift in cervical cancer control in a resource-constrained 
setting like Nigeria and other parts of sSA.
Protocol
Study design
This study (mHealth-Cervix) is a multi-center randomized 
controlled trial that will involve women aged 25 to 65 years 
who are attending the General Outpatient (GOP) clinics of two 
public tertiary health institutions in Lagos, Nigeria – Lagos 
University Teaching Hospital (LUTH), Idi-Araba and Lagos 
State University Teaching Hospital (LASUTH), Ikeja between 
April and December 2020. The trial protocol has been reg-
istered in the Pan African Clinical Trial Registry (PACTR) 
(PACTR202002753354517; version 3.0; February 13, 2020).
Study settings
LUTH and LASUTH are the two foremost public tertiary health 
institutions in Lagos that offer speciality and sub-speciality care 
including gynaecological oncology services such as Papanicolaou 
(Pap) test, human papillomavirus (HPV) testing and colpos-
copy for cervical cancer screening. The GOP clinics of the two 
hospitals run from Monday to Friday each week and attend-
ees at the clinics are mostly enrollees of the National Health 
Insurance Scheme (NHIS) who have free cervical cancer screening 
as part of their health coverage. The hospitals act mainly as 
referral centers for other government-owned and private 
hospitals in Lagos State. Lagos State is the commercial capital of 
Nigeria which has a population of over 9 million inhabitants.
Study population and eligibility criteria
Eligible women are NHIS enrollees aged between 25 and 65 
with no prior history of cervical cancer or cervical dysplasia; 
those not adherent with current recommendations for Pap smear 
screening (have not had a Pap smear within the last three years); 
those owning and using a personal cell-phone; those free from 
any mental or physical disabilities that inhibit them from under-
standing the implications of the study and those not considering 
relocating from their current residence within the next year. The 
exclusion criteria include women younger than 25 and older 
than 65 years old, those with history of cervical dysplasia 
and cancer, those who had a Pap test within the last three years, 
those with an ongoing pregnancy and those who refuse or 
withdraw consent during the study.
Participants’ enrollment and data collection
Investigators will identify eligible women from the GOP clin-
ics of the two study sites on each day of the study period after 
which a 20–30 minutes educational health talk on cervical 
cancer and its prevention is given to these women by the clinic 
midwives with the assistance of the clinics’ health care teams 
as part of their usual standard of care. Eligible women are then 
invited by the investigators to give consent for participation in 
the clinical trial upon explanation of the purpose and nature of 
the study. Once consent is obtained, an interviewer-administered 
questionnaire (see extended data17) is then used to obtain 
baseline information on sociodemographic variables, cell-phone 
use, and distance of participants’ residence from the clinics 
(measured in kilometer using the Google maps). Each woman 
will receive an estimated $5 credit charge on their cellphones as a 
token to enable the investigators to keep their phone numbers for as 
long as the intervention lasts. The women in both arms are each 
given the complementary card containing the cell-phone number 
of the cytology clinic coordinators (who are also part of the 
study) and are subsequently scheduled for 6-month follow-up 
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appointments from their dates of study enrolment. After 
follow-up, data will be collected from each woman on completion 
of Pap test screening, the number of GOP clinics attended, 
the interval from enrollment to date of Pap smear testing 
and functionality of cell-phone during the same follow-up 
period (that is, if the cell-phone was in use for at least 5 out the 
6 months follow-up or not).
Randomization
Following the baseline assessment, enrolled women will be ran-
domized to either a text message (intervention) arm or usual 
care (control) arm using computer-generated block randomi-
zation codes using Random Allocation software version 1.0 
(May 2004) by a study statistician. Investigators and statisti-
cians will be blinded to the allocation groups [Figure 1]. The 
allocation sequence is concealed in sealed opaque envelopes 
that will be kept in a locked file cabinet at each of the study sites 
until participants assignment is completed.
Intervention (mHealth) arm – We chose Nexmo® as the plat-
form to deliver the mHealth messages given its low cost and 
reliability. Participants will be sent messages containing 
information and encouragement to undergo cervical cancer 
screening. Information will also be provided about the Cytology 
clinic hours, contact information and locations in the two par-
ticipating hospitals. Information and motivational text messages 
will be  delivered twice monthly for the next 6-months after 
enrollment.
Usual care (control) arm – Participants randomized to the con-
trol arm will not receive additional reminder messages from 
study staff other than the usual care received at enrollment. 
Usual care consists of any information on Pap tests and cervical 
cancer risk reduction typically provided by midwives to all 
women at the clinics as will be done at enrollment. These women 
can then schedule an appointment for their Pap smear testing 
in person at the GOP or Cytology clinics at any time during 
the 6-month follow-up period.
Study endpoints
Primary endpoint – This is the completion of a Pap smear within 
6 months of enrollment in the study. Participants will be tracked 
via medical record review as well as through phone calls at 
6-month after their enrolment.
Figure 1. Trial flow chart.
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Secondary endpoint – This is an assessment of the various fac-
tors affecting Pap smear uptake or adherence within 6-month of 
enrollment among the participating women.
Statistical methods
Sample size – We calculated sample size using G*Power for 
Windows version 3.1.9.2 (Kiel University, Germany). Using 
data from our published study6, we estimated the proportion of 
Pap smear adherence to be approximately 23% for the usual care 
(control) arm and 60% for the text message (intervention) arm. 
This is powered for a two-sided test with a Type I error rate of 
5% and 80% power, i.e. Zα=1.96 and Zβ=0.84, adjusted for 
a 10% attrition rate. Therefore, the power calculations will be 
based on a sample size of 100 in each of the two study arms 
(making a total sample size of 200).
Statistical analysis – The intention-to-treat principle will be 
used in the final analyses. Statistical analyses will be carried 
out using SPSS version 23.0 for Windows (Armonk, NY: IBM 
Corp.). Pap smear adherence will be coded as a binary variable. 
The intervention will be evaluated based only on Pap smear com-
pletion at 6-month after the enrollment and baseline survey. The 
associations between any two groups of continuous variables 
will be tested using the independent sample t-test (normal dis-
tribution) or the Mann-Whitney U test (skewed data) and that of 
two groups of categorical variables with Chi-square (χ2) or 
Fisher’s exact test where appropriate. Using binary logistic 
regression analysis, we will adjust for age, socioeconomic class, 
parity, marital status, number of GOP clinic attendance, the 
distance of residence from the clinics, interval from enrollment 
to date of Pap smear testing, the functionality of cellphones and 
other relevant demographic and clinical variables. Statistical 
significance will be defined as P-value less than 0.05.
Quality control and data monitoring
All investigators and research assistants will be required to 
undergo training before the trial to guarantee consistent practice. 
The training will include an understanding of inclusion/exclusion 
criteria, follow-up procedures, and completion of the ques-
tionnaire. Identifiable data will be transferred to an electronic 
database system located in a guarded facility at the trial site by 
the research assistant. Access to identifiable data is restricted only 
to the PI during and after the trial completion. The trial will be 
monitored by quality assurance personnel from the research man-
agement office of the College of Medicine, University of Lagos, 
who will be independent of the study team, and an independent 
steering committee. There will be periodic monitoring to guar-
antee accuracy and quality throughout the study period. The 
essential documents (consent information, enrolment, protocol 
deviations, and losses to follow-up) will be monitored and checked 
for accuracy and completeness by the monitors. The princi-
pal investigator (KSO) is responsible for the overall project and 
for organizing steering committee meetings. The independent 
steering committee will be responsible for ensuring the overall 
safety of participants, coordinating study meetings, supervising 
the study, monitoring data safety, and overseeing quality control.
Ethics
This study protocol was approved by the Health Research 
Ethics Committee of College of Medicine, University of Lagos 
(CMUL HREC) on 2nd February 2020 with approval number 
CMUL/HREC/12/19/704. Participants will provide written 
informed consent before their participation in the trial and the 
participant will keep a signed copy of the consent form for 
future references.
Dissemination of information
The trial will be reported in line with the Consolidated Stand-
ards of Reporting Trials (CONSORT) checklist and the results 
will be disseminated in peer-review scientific journals. Important 
modifications to the trial protocol will be communicated 
to the funder, study investigators, CMUL HREC, trial participants 
and trial registries.
Study status
At the time of initial manuscript submission, recruitment is 
yet to commence into the trial. Participants’ enrolment will 
start in May 2020, and the last woman is expected to be 
included in the trial in July 2020. The manuscript reports 
protocol version 3.0 (30th March 2020).
Discussion
Cervical cancer is a major public health disease in Nigeria. 
However, screening is still not a national priority as only 23% 
of adult females has ever been screened6. There is wide use of 
mobile technologies in Nigeria and most parts of sub-Saharan 
Africa, but there are currently no randomized controlled tri-
als that have described the use of these technologies for cancer 
screening. This protocol describes a randomised controlled 
trial of a novel intervention (mHealth technologies using text 
messages) to improve Pap smear screening adherence among 
women in Lagos. The mHealth-Cervix study will evaluate the 
impact of mobile technologies on cervical cancer screening 
practices in Lagos, Nigeria and determine the factors that affect 
this screening adherence as a means of reducing the dispari-
ties in the incidence of cervical cancer through early detection 
facilitated using health promotion to improve Pap smear screen-
ing adherence. If found to be effective in increasing adherence 
to screening, the mHealth intervention strategy may become 
an important tool for reducing the cervical cancer burden, 
and its associated morbidity and mortality. This could also be 
applied in the future for the health promotion and prevention 
of other major disease conditions.
Data availability
Underlying data
No data are associated with this article
Extended data
Harvard Dataverse: Replication Data for: Impact of mobile 
technologies on cervical cancer screening practices in Lagos, 
Nigeria (mHealth-Cervix): Protocol for a randomised controlled 
trial https://doi.org/10.7910/DVN/GXE1ON17
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This trial protocol contains the following underlying data:
• Consent form.pdf (Study consent form)
• Questionnaire_f1000.docx
Reporting guidelines
SPIRIT checklist for “Impact of mobile technologies on 
cervical cancer screening practices in Lagos, Nigeria (mHealth-
Cervix): Protocol for a randomised controlled trial” https://doi.
org/10.7910/DVN/GXE1ON17
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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The research addresses the importance of improving compliance with cervical screening using mobile
phone technology. I am not familiar with the platform described and would suggest another reviewer
comments on the appropriateness.
 
This manuscript presents methods but no results yet. I suggest the paper will make for more interesting
reading when results are available. Also the endpoints of the study are attendance for screening. As the
purpose of screening is to prevent cervical cancer, a more important goal will be difference in outcome
between the two study groups in terms of detection rates of premalignant lesions and eventual outcome. I
appreciate the numbers may be too small to demonstrate a reduction in cervical cancer.
 
Finally I question why cervical smears are the chosen screening methods when all available data indicate
that HPV testing is more reliable and objective and is indeed the method of choice in the national cancer
plan.
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